Trial Profile
A Phase 2A Partially-Blind Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of Live Attenuated, Intranasal B. Pertussis Vaccine (BPZE1) in Healthy Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2022
Price :
$35
*
At a glance
- Drugs BPZE 1 (Primary)
- Indications Pertussis
- Focus Adverse reactions
- 08 Oct 2022 Results published in the Vaccine
- 27 Jun 2022 According to a ILiAD Biotechnologies media release, data from this study will be presented at the 13th International Bordetella Symposium.
- 21 May 2020 Status changed from active, no longer recruiting to completed.